{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:38:39Z","timestamp":1778661519383,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.bulcan.2015.09.001","type":"journal-article","created":{"date-parts":[[2015,10,25]],"date-time":"2015-10-25T21:51:37Z","timestamp":1445809897000},"page":"906-914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tol\u00e9rance r\u00e9novasculaire du b\u00e9vacizumab dans le cancer du sein. Valeur pronostique de l\u2019hypertension et de la prot\u00e9inurie"],"prefix":"10.1016","volume":"102","author":[{"given":"Vincent","family":"Launay-Vacher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Janus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Beuzeboc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Selle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Rey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Jouannaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Philippe","family":"Spano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Thery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Morere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Goldwasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Mir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Scott\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Dorent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert","family":"Deray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Gligorov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2015.09.001_bib0145","series-title":"Les donn\u00e9es","author":"Institut national du cancer","year":"2012"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0150","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.clinthera.2006.11.015","article-title":"Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies","volume":"28","author":"Shih","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CAD.0b013e3283161012","article-title":"Hypertension and proteinuria: a class-effect of antiangiogenic therapies","volume":"20","author":"Launay-Vacher","year":"2009","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0160","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.ajkd.2007.04.025","article-title":"Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension","volume":"50","author":"Izzedine","year":"2007","journal-title":"Am J Kidney"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0165","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.ejca.2006.09.015","article-title":"The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors: a review","volume":"42","author":"Eskens","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0170","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/ndt\/gfn657","article-title":"Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib","volume":"24","author":"Boll\u00e9e","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0175","first-page":"612","article-title":"A case of thrombotic microangiopathy with glomerular subendothelial IgA deposition due to bevacizumab","volume":"56","author":"Tomita","year":"2014","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0180","first-page":"H1054","article-title":"VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells","volume":"274","author":"Hood","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0185","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10456-004-2699-3","article-title":"Angiogenic growth factors and hypertension","volume":"7","author":"Sane","year":"2004","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0190","doi-asserted-by":"crossref","first-page":"143426","DOI":"10.1155\/2014\/143426","article-title":"Anti-VEGF cancer therapy in nephrology practice","volume":"2014","author":"Izzedine","year":"2014","journal-title":"Int J Nephrol"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0195","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0200","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0205","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0210","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0215","article-title":"Results of the MARS study on the management of antiangiogenics\u2019 renovascular safety in colorectal cancer","volume":"32","author":"Ray-Coquard","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0220","article-title":"Results of the MARS study on the management of antiangiogenics\u2019 renovascular safety in renal cell carcinoma","volume":"32","author":"Ray-Coquard","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0225","article-title":"Results of the MARS study on the management of antiangiogenics\u2019 renovascular safety in lung cancer","volume":"49","author":"Goldwasser","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0230","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.5567","article-title":"Results of the MARS study on the management of antiangiogenics\u2019 renovascular safety in ovarian cancer","volume":"31","author":"Launay-Vacher","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0235","series-title":"Find medicine \u2013\u00a0Avastin","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0240","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0245","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2 \u2013 negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0250","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0255","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/annonc\/mdq430","article-title":"First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients","volume":"22","author":"Smith","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0260","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1634\/theoncologist.2012-0339","article-title":"Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies","volume":"18","author":"Hurwitz","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0265","first-page":"3039","article-title":"Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV)","volume":"28","author":"Hurwitz","year":"2010","journal-title":"ASCO Meet Abstr"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0270","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.nephro.2008.10.002","article-title":"Vascular and renal effects of antiangiogenic therapy","volume":"4","author":"Halimi","year":"2008","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0275","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1684\/bdc.2011.1477","article-title":"Renal toxicity of contrast agents in oncologic patients","volume":"99","author":"Amet","year":"2012","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.bulcan.2015.09.001_bib0140","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S1470-2045(10)70232-1","article-title":"Biomarkers to predict the clinical efficacy of bevacizumab in cancer","volume":"11","author":"Jubb","year":"2010","journal-title":"Lancet Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115002738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115002738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T07:36:54Z","timestamp":1599723414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115002738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0007455115002738"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2015.09.001","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tol\u00e9rance r\u00e9novasculaire du b\u00e9vacizumab dans le cancer du sein. Valeur pronostique de l\u2019hypertension et de la prot\u00e9inurie","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2015.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}